New GnRH blocker degarelix quickly suppresses levels of testosterone

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 6
Volume 17
Issue 6

ORLANDO-In a phase III study, the investigational GnRH blocker degarelix (Ferring Pharmaceuticals) significantly reduced testosterone levels within 3 days in more than 96% of study patients, Laurence Klotz, MD, of the University of Toronto, reported at AUA 2008. The fast effect on testosterone levels was close to the immediate effect achieved with surgery, he said.

ORLANDO-In a phase III study, the investigational GnRH blocker degarelix (Ferring Pharmaceuticals) significantly reduced testosterone levels within 3 days in more than 96% of study patients, Laurence Klotz, MD, of the University of Toronto, reported at AUA 2008. The fast effect on testosterone levels was close to the immediate effect achieved with surgery, he said.

The 12-month randomized, open-label, parallel-group study compared monthly subcutaneous administration of degarelix with monthly injection of the LHRH agonist leuprolide depot 7.5 mg in hormone-dependent prostate cancer patients. The degarelix patients received 240 mg at baseline and then were randomized to receive 80 or 160 mg monthly.

By day 3, testosterone levels were suppressed to ≤ 0.5 ng/mL in 96.1% of patients in the degarelix arms vs 0% in the leuprolide arm. By day 14, 100% of degarelix patients achieved testosterone suppression to ≤ 0.5 ng/mL vs 18.2% on leuprolide. After 14 days, PSA levels had declined in the degarelix-treated patients by a median of 64% vs 18% for leuprolide.

Recent Videos
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video
2 experts are featured in this series.
4 experts in this video
5 experts are featured in this series
Related Content